Mon, June 9, 2025
[ Yesterday Morning ] - Townhall
Tom Homan Hammers Whiny Newsom
Sun, June 8, 2025
Sat, June 7, 2025
Fri, June 6, 2025
Thu, June 5, 2025
Wed, June 4, 2025
Tue, June 3, 2025
Mon, June 2, 2025
Sun, June 1, 2025
Sat, May 31, 2025
Fri, May 30, 2025
Thu, May 29, 2025
[ Thu, May 29th ] - rnz
A step up in fake news
Wed, May 28, 2025
Tue, May 27, 2025
Mon, May 26, 2025
Sun, May 25, 2025
Sat, May 24, 2025
Fri, May 23, 2025
Thu, May 22, 2025
Wed, May 21, 2025
[ Wed, May 21st ] - Politico
Inside Congress Live

Metsera's drug shows potential in early clinical trial


//politics-government.news-articles.net/content/ .. rug-shows-potential-in-early-clinical-trial.html
Published in Politics and Government on by STAT   Print publication without navigation

And other biotech news stories brought to you by The Readout.

The article from STAT News dated June 9, 2025, discusses several key developments in the biotech industry. Merck has acquired Eyebiotech for $3 billion to bolster its ophthalmology offerings, while Keros Therapeutics reported positive results from a Phase 2 trial of KER-050 for treating anemia in patients with myelodysplastic syndromes. Metsera, a new company focused on metabolic diseases, launched with $290 million in funding. Axsome Therapeutics received FDA approval for its migraine treatment, AXS-07. The European Medicines Agency (EMA) is set to review the safety of GLP-1 receptor agonists due to concerns over potential side effects. Additionally, the National Institutes of Health (NIH) is facing budget cuts that could impact research funding. Lastly, Amylin Pharmaceuticals is exploring a potential acquisition to expand its portfolio in diabetes and obesity treatments.

Read the Full STAT Article at:
[ https://www.statnews.com/2025/06/09/biotech-news-merck-keros-metsera-axsome-ema-nih-cuts-amylin-the-readout/ ]

Publication Contributing Sources